ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that an abstract on its bispecific protein therapeutic targeting prostate cancer has been accepted for presentation at the 24th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 6-9, 2012 in Dublin, Ireland. The preclinical results showed Emergent’s SCORPIONTM (multi-specific protein therapeutic) molecules targeting prostate-specific membrane antigen (PSMA) and CD3 redirected T-cell cytotoxicity against PSMA-positive tumor cells and show potential for further investigation as possible therapeutic agents for treating castrate-resistant prostate cancer. T-cell engaging bispecific molecules linking anti-PSMA and anti-CD3 binding domains in the context of novel SCORPION proteins were evaluated both in vitro and in vivo for function and stability.
